Erlotinib (Standard)

Erlotinib (Standard) is the analytical standard of Erlotinib. This product is intended for research and analytical applications. Erlotinib (CP-358774) is a directly acting EGFR tyrosine kinase inhibitor, with an IC50 of 2 nM for human EGFR. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer[1]. Erlotinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Product Specifications

CAS Number

[183321-74-6]

Product Name Alternative

CP-358774 (Standard) ; NSC 718781 (Standard) ; OSI-774 (Standard)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; EGFR; Reference Standards

Type

Reference Standards

Related Pathways

Autophagy; JAK/STAT Signaling; Others; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/erlotinib-standard.html

Purity

99.97

Smiles

C#CC1=CC=CC(NC2=NC=NC3=C2C=C(C(OCCOC)=C3)OCCOC)=C1

Molecular Formula

C22H23N3O4

Molecular Weight

393.44

Precautions

H302, H315, H319, H335

References & Citations

[1]Moyer JD, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997, 57 (21), 4838-4848.|[2]Ali S, et al. Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. Mol Cancer Ther, 2008, 7 (6), 1708-1719.|[3]Wada Y, et al. Epidermal growth factor receptor inhibition with erlotinib partially prevents cisplatin-induced nephrotoxicity in rats. PLoS One. 2014 Nov 12;9 (11) :e111728.